UiPath (NYSE:PATH) Trading 0.9% Higher

UiPath Inc. (NYSE:PATH)’s stock price was up 0.9% during trading on Wednesday . The stock traded as high as $12.09 and last traded at $12.04. Approximately 1,389,684 shares changed hands during trading, a decline of 86% from the average daily volume of 9,836,723 shares. The stock had previously closed at $11.93.

Analysts Set New Price Targets

Several equities analysts recently commented on PATH shares. Barclays cut their target price on shares of UiPath from $25.00 to $16.00 and set an “equal weight” rating for the company in a research note on Thursday, May 30th. JPMorgan Chase & Co. cut their target price on shares of UiPath from $28.00 to $19.00 and set an “overweight” rating for the company in a research note on Thursday, May 30th. KeyCorp reiterated a “sector weight” rating on shares of UiPath in a research note on Thursday, May 30th. Needham & Company LLC restated a “hold” rating on shares of UiPath in a research note on Thursday, May 30th. Finally, Scotiabank dropped their price objective on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a research note on Wednesday, May 29th. Sixteen research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $18.06.

UiPath Trading Up 3.8 %

The business’s fifty day simple moving average is $16.30 and its 200 day simple moving average is $20.89.

UiPath (NYSE:PATH) last issued its quarterly earnings data on Wednesday, May 29th. The healthcare company reported ($0.03) EPS for the quarter, hitting analysts’ consensus estimates of ($0.03). UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The firm had revenue of $335.11 million for the quarter, compared to analyst estimates of $332.84 million. On average, equities analysts forecast that UiPath Inc. will post -0.2 earnings per share for the current year.

Insiders Place Their Bets

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $19.79, for a total transaction of $791,600.00. Following the sale, the chief financial officer now owns 946,848 shares of the company’s stock, valued at approximately $18,738,121.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 22.37% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Cetera Advisors LLC lifted its position in UiPath by 93.5% during the 1st quarter. Cetera Advisors LLC now owns 19,706 shares of the healthcare company’s stock valued at $447,000 after purchasing an additional 9,522 shares during the period. Cetera Investment Advisers lifted its position in UiPath by 315.6% during the 1st quarter. Cetera Investment Advisers now owns 67,782 shares of the healthcare company’s stock valued at $1,537,000 after purchasing an additional 51,472 shares during the period. Strategic Wealth Partners Ltd. acquired a new position in UiPath during the 1st quarter valued at about $641,000. Plato Investment Management Ltd lifted its position in UiPath by 1,271.0% during the 1st quarter. Plato Investment Management Ltd now owns 39,978 shares of the healthcare company’s stock valued at $906,000 after purchasing an additional 37,062 shares during the period. Finally, Comerica Bank lifted its position in UiPath by 226.5% during the 1st quarter. Comerica Bank now owns 25,154 shares of the healthcare company’s stock valued at $570,000 after purchasing an additional 17,451 shares during the period. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.